Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00743288 · ClinicalTrials.gov registry record · Phase 1
Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma
A Phase 1 study, sponsored by Oncotherapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00743288 is a Phase 1 study that has completed, run by Oncotherapeutics. The registered enrollment target is 40 participants.
The verdict
NCT00743288, a Phase 1 study, has completed, sponsored by Oncotherapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving melphalan together with panobinostat may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of melphalan when given together with panobinostat in treating patients with recurrent multiple myeloma.
Interventions
- DRUG Melphalan
- DRUG Panobinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-07 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00743288
The ClinicalTrials.gov registry entry for NCT00743288 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oncotherapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Melphalan is the first listed.
NCT00743288 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00743288 about?
NCT00743288 is a clinical study titled "Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma". RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving melphala...
What is the current status of trial NCT00743288?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2008-07. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00743288?
The interventions under investigation include: Melphalan (DRUG), Panobinostat (DRUG).
Who is sponsoring clinical trial NCT00743288?
This trial is sponsored by Oncotherapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.